Cargando…
利妥昔单抗追加治疗对初次完全缓解的弥漫大B细胞淋巴瘤患者的疗效评估
OBJECTIVE: To analyze the efficacy of additional two cycles of rituximab administration for Chinese patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) after six cycles of standard 21-day rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHO...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342108/ https://www.ncbi.nlm.nih.gov/pubmed/27719717 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.006 |